Navigation Links
New PAREXEL Report Defines The Next Generation Of Strategic Partnerships Between CROs And Biopharmaceutical Industry
Date:4/22/2013

ted with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2012 as filed with the SEC on February 1, 2013, which "Risk Factors" discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

© 2013 PAREXEL International Corporation.  PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a registered trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Info
'/>"/>

SOURCE PAREXEL International
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PAREXEL International Provides Update On Share Repurchase Program, Announces A New $50 Million Accelerated Share Repurchase Agreement And A New $50 Million 10b5-1 Trading Plan
2. PAREXEL International To Present At Raymond James Investors Conference And Barclays Capital Healthcare Conference
3. PAREXEL International To Present At Citi Global Healthcare Conference
4. PAREXEL International Reports Second Quarter Fiscal Year 2013 Results
5. PAREXEL International To Present At Oppenheimer Healthcare Conference
6. PAREXEL International To Present At Lazard Capital Healthcare Conference And Jefferies Global Healthcare Conference
7. PAREXEL and Salem State University Launch Clinical Trial Management Graduate Program
8. PAREXEL International to Present at Robert Baird Healthcare Conference
9. PAREXEL Strengthens Outcomes Research Capabilities To Help Biopharma Meet Commercialization Goals
10. PAREXEL Launches The PAREXEL BioPharm Unit To Meet The Critical Development Goals Of Small And Mid-Sized Biopharmaceutical Companies
11. PAREXEL And Korea Drug Development Fund Announce Alliance To Accelerate Global Drug Development And Commercialization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014  United Therapeutics Corporation (NASDAQ: ... for the District of New Jersey ... case against Sandoz, Inc. regarding United Therapeutics, Remodulin ® ... ruled that U.S. Patent No. 6,765,117 is both valid ... marketing its generic product until the expiration of that ...
(Date:8/29/2014)... -- Diseases largely eradicated in the United ... was declared eliminated in 2000, yet the CDC reports ... highest incidence in 20 years. In July, ... a problem of "epidemic proportions." ... these preventable diseases—in part because some parents (more than ...
(Date:8/29/2014)... DUBLIN , Aug. 29, 2014 ... the "Global Multiple Sclerosis Drugs Market 2014-2018" ... is a chronic, inflammatory medical condition that results in ... damaged because of an abnormal response by the immune ... (CNS). It is a potentially debilitating disease in which ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... Ala., Dec. 14 BioCryst,Pharmaceuticals, Inc. (Nasdaq: ... data evaluating forodesine HCl, the Company,s lead anti-cancer,compound, ... and lymphomas., Madeline Duvic, M.D., Deputy Chair, ... presented interim data from the Phase,I/II clinical study ...
... the Treatment of PKU, NOVATO, Calif., Dec. ... announced today that the U.S.,Food and Drug Administration ... Tablets, the first specific drug,therapy approved for the ... will commence tomorrow, and BioMarin will begin,promotion of ...
Cached Medicine Technology:Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma 2Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma 3Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma 4BioMarin Announces FDA Approval for Kuvan 2BioMarin Announces FDA Approval for Kuvan 3BioMarin Announces FDA Approval for Kuvan 4BioMarin Announces FDA Approval for Kuvan 5BioMarin Announces FDA Approval for Kuvan 6BioMarin Announces FDA Approval for Kuvan 7BioMarin Announces FDA Approval for Kuvan 8
(Date:8/29/2014)... a systematic review of clinical trials based on ... researchers have concluded that more trials are needed ... for postsurgical pain on a regular basis., Dr. ... pain research in the Department of Anesthesiology, and ... to determine whether the use of antidepressants for ...
(Date:8/29/2014)... Colo. (Sept. 2, 2014) A team of scientists ... reported the breakthrough discovery of a process to expand ... These findings could have implications that extend beyond cancer, ... autoimmune diseases., In an article published Aug. ... Charles C. Gates Center for Regenerative Medicine and Stem ...
(Date:8/29/2014)... Mass. (August 29, 2014, 2 PM US Eastern ... is to inject antibodies, commonly produced in animals, ... challenges ranging from safety to difficulties in developing, ... , New research led by Charles Shoemaker, ... and Global Health at the Cummings School of ...
(Date:8/29/2014)... EDMONTON, AB A new study from the research group ... AB) and the Lawson Health Research Institute (London, ON) has ... of cancer. The study, published in Cell Reports , ... spread of cancer entirely. , Roughly 2 in 5 ... four of them will die of the disease. In 2014, ...
(Date:8/29/2014)... Francisco, CA (PRWEB) August 30, 2014 ... 10 best web conference providers in the online service ... the list were global leaders Webex, GotoMeeting and Infinite. ... the industry users have to determine which provider is ... Essentially, web conference businesses search for compelling consumer goods ...
Breaking Medicine News(10 mins):Health News:Antidepressants show potential for postoperative pain 2Health News:CU scientists' discovery could lead to new cancer treatment 2Health News:Mice study shows efficacy of new gene therapy approach for toxin exposures 2Health News:Preventing cancer from forming 'tentacles' stops dangerous spread 2Health News:Top10InAction Reveals Best Web Conference Providers 2
... WASHINGTON, Sept. 2 Speaker Nancy Pelosi and Senate Majority Leader Harry Reid ... Session of Congress on Wednesday, September 9, 2009. , , ... , September 2, 2009 , , President Barack ... Dear Mr. President: , , Our nation is closer than ever ...
... ATLANTA, Sept. 2 /PRNewswire-FirstCall/ -- Gentiva Health Services, Inc. ... health services, announced today that it has completed its acquisition of ... the Rush Health System, located in central Mississippi and west central ... , "We extend a warm welcome to all ...
... , , WASHINGTON, Sept. ... President, Campaign for Tobacco-Free Kids: , , (Logo: ... have taken decisive action to protect the state,s kids and taxpayers from ... by $1 to $3.00 per pack, making it the second highest state ...
... Study found more than half of advanced basal cell carcinomas ... -- An experimental cancer drug that switches off the so-called ... patients with advanced basal cell carcinoma, a type of skin ... from medulloblastoma, the most common form of brain cancer in ...
... , OAKLAND, Calif., Sept. 2 Wigix ( ... database on the web. Wigix has surpassed Overstock.com and ... (Source: Internet Retailers Top 500 Guide 2009 Edition) , , ... thousand SKUs during its public beta launch in June 2007. This milestone marks ...
... , , , ... the House Democrat healthcare bill (H.R. 3200) that violate President Obama,s promise ... $250,000 per year. The White House has told reporters that Obama ... week, which begs the question: , , ...
Cached Medicine News:Health News:Gentiva(R) Health Services Completes Acquisition of Home Health Agency 2Health News:Gentiva(R) Health Services Completes Acquisition of Home Health Agency 3Health News:Connecticut Cigarette Tax Increase Delivers Victory for Kids and Taxpayers; $1 Increase Gives State Second Highest Cigarette Tax in the Nation 2Health News:Connecticut Cigarette Tax Increase Delivers Victory for Kids and Taxpayers; $1 Increase Gives State Second Highest Cigarette Tax in the Nation 3Health News:New Compound Shrinks Skin Cancers 2Health News:New Compound Shrinks Skin Cancers 3Health News:New Compound Shrinks Skin Cancers 4Health News:Wigix Announces 1 Million in Open Sell Orders 2Health News:Obama's 'Specific' Healthcare Speech: Will He Disavow Pledge-Breaking Tax Hikes in House Dem Health Bill? 2
Stainless steel construction to withstand sterilization modalities (EtO) Wide angle of view...
Inquire...
ENDOlap™ laparoscopes provide excellent image linearity and flatness of field....
The Fujinon's R410 laparoscope is the first to bring a 410,000 pixel CCD to the end of the scope. Superior imaging and color replication, along with a unique lens washing capability make the R410 the...
Medicine Products: